Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 7/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10164566 | 0.93 | TRPA1 (0.41) | TSHRTRPA1KDM4EALDH1A1TP53 | |
| SCHEMBL894182 | 0.92 | TSHR (0.46) | TSHRMAPK1TRPA1 | |
| SCHEMBL10164519 | 0.92 | TRPA1 (0.41) | TRPA1ALDH1A1TP53 | |
| SCHEMBL10164517 | 0.88 | TSHR (0.61) | TSHRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10164627 | 0.87 | TRPA1 (0.42) | TRPA1TP53 | |
| SCHEMBL10164568 | 0.86 | TSHR (0.49) | TSHRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10164549 | 0.85 | TSHR (0.50) | TSHRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10164512 | 0.85 | LMNA (0.44) | TRPA1TP53 | |
| SCHEMBL894366 | 0.85 | TRPA1 (0.45) | TRPA1 | |
| SCHEMBL894519 | 0.85 | TRPA1 (0.45) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | TSHR 2952/4885CYP3A4 1670/4885CYP2D6 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.